Formulary Search Results for: CALCIUM AND VITAMIN D
9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias - View Category
Restrictions:
Restricted to specialist use only in accordance with the Prescribing Notes below.
Prescribing Notes:
Formulary indications:
- Treatment of chronic iron overload associated with the treatment of rare acquired or inherited anaemias requiring recurrent blood transfusions when deferoxamine therapy is contraindicated or inadequate
- Treatment of myeloplastic syndrome (MDS) in patients with an International Prognostic Scoring System (IPSS) score of low or intermediate -1 risk when deferoxamine therapy is contraindicated or inadequate in accordance with regional protocol (in development)
It is not recommended by SMC for:
- Treatment of patients with chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes and is non-Formulary for these indications.
9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias - View Category
9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias - View Category
Restrictions:
Restricted to specialist initiation. Approved in NHSGGC only for anaemia associated with renal failure. This is the preferred Formulary agent for this indication.
9.2.1.1 Oral potassium - View Category
Restrictions:
For use within the acute (hospital) sector only.
Prescribing Notes:
Please note, different preparations of calcium polystyrene sulphonate may require different dosing schedules.
9.2.1 Oral preparations for fluid and electrolyte imbalance - View Category
9.2.2.2 Plasma and plasma substitutes - View Category
9.5.1.1 Calcium supplements - View Category
9.5.1.1 Calcium supplements - View Category
9.5.1.1 Calcium supplements - View Category
9.5.1.3 Magnesium - View Category
Prescribing Notes:
It is important to establish the underlying cause of the hypomagnesaemia, rather than simply treating the deficiency.